Blocking the Enzyme That Destroys Natriuretic Peptides Enhances Their Blood Pressure-Lowering Effects
Inhibiting neutral endopeptidase (NEP) significantly enhanced the blood pressure-lowering, hormonal, and kidney effects of ANP, BNP, and CNP in hypertensive rats.
Quick Facts
What This Study Found
NEP inhibition with thiorphan significantly potentiated the blood pressure-lowering, hormonal, and renal effects of all three natriuretic peptides (ANP, BNP, CNP) in hypertensive transgenic rats.
Key Numbers
How They Did This
Hypertensive transgenic rats (with extra renin gene) received infusions of ANP, BNP, or CNP with or without the NEP inhibitor (S)-thiorphan. Blood pressure, hormonal, and renal responses were measured.
Why This Research Matters
This study provided preclinical evidence for the NEP inhibitor strategy that eventually led to the development of sacubitril/valsartan (Entresto), now a standard heart failure treatment.
The Bigger Picture
This study contributed to the rationale for neprilysin inhibitors in cardiovascular medicine — sacubitril, a NEP inhibitor, is now combined with valsartan (Entresto) as a leading heart failure treatment.
What This Study Doesn't Tell Us
Animal study using genetically modified hypertensive rats. Results may not directly translate to human heart failure. Acute infusion protocol doesn't address chronic treatment effects.
Questions This Raises
- ?Could NEP inhibitors alone or combined with natriuretic peptides treat human hypertension?
- ?Which natriuretic peptide benefits most from NEP inhibition?
Trust & Context
- Key Stat:
- All 3 peptides enhanced NEP inhibition potentiated the effects of ANP, BNP, and CNP in blood pressure, hormones, and kidney function
- Evidence Grade:
- Moderate animal evidence in a well-characterized hypertension model. Strong preclinical support for the NEP inhibitor strategy.
- Study Age:
- Published in 1996, this study contributed to the evidence base for sacubitril/valsartan (Entresto), approved 2015 for heart failure.
- Original Title:
- Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats.
- Published In:
- Hypertension research : official journal of the Japanese Society of Hypertension, 19(4), 229-38 (1996)
- Authors:
- Wegner, M(2), Ganten, D, Stasch, J P(2)
- Database ID:
- RPEP-00392
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is NEP?
Neutral endopeptidase (NEP, also called neprilysin) is an enzyme that breaks down natriuretic peptides in the blood. By destroying these heart-protective peptides, NEP limits their beneficial effects on blood pressure and fluid balance.
How does this relate to Entresto?
Entresto contains sacubitril, an NEP inhibitor, combined with valsartan. By blocking NEP, sacubitril lets natriuretic peptides work longer and harder — exactly the principle demonstrated in this study. Entresto is now a cornerstone heart failure medication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00392APA
Wegner, M; Ganten, D; Stasch, J P. (1996). Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats.. Hypertension research : official journal of the Japanese Society of Hypertension, 19(4), 229-38.
MLA
Wegner, M, et al. "Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats.." Hypertension research : official journal of the Japanese Society of Hypertension, 1996.
RethinkPeptides
RethinkPeptides Research Database. "Neutral endopeptidase inhibition potentiates the effects of ..." RPEP-00392. Retrieved from https://rethinkpeptides.com/research/wegner-1996-neutral-endopeptidase-inhibition-potentiates
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.